A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

This study is testing a combination of two cancer drugs — RC48-ADC (a targeted antibody-drug) and zimberelimab (an immunotherapy) — in women with cervical cancer that has come back or spread, and has stopped responding to standard platinum-based chemotherapy. **You may be eligible if...** - You are a woman aged 18 or older - You have been diagnosed with recurrent or metastatic cervical cancer confirmed by biopsy - Your cancer has the HER2 protein (any level of expression) - You have tried at least one prior standard chemotherapy treatment containing platinum and it did not work - You are not a suitable candidate for surgery or radiation - Your expected survival is at least 12 weeks - Your general health and organ function meet study requirements **You may NOT be eligible if...** - You have not yet tried standard chemotherapy - You are still able to receive surgery or radiation - Your cancer does not express the HER2 protein - Your organ function or overall health does not meet the required thresholds Talk to your doctor to see if this trial is right for you.